Overview Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indicator: In combination with chemotherapy, for your remedy of Grownup clients with regionally recurrent unresectable or metastatic triple-negative breast most cancers which have not received prior chemotherapy for metastatic disorder and whose tumours Convey programmed cell death-ligand one (blended positive score ≥ 10) as https://lloydw468wyb3.blogsidea.com/profile